Sutro Biopharma, a California based, clinical-stage company, announced initial safety data in ovarian cancer patients from its ongoing phase I study (NCT03748186) of STRO-002. The drug is a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) and potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models.
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience.
The data are being presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019.
As per a recent market report by Roots Analysis, in the ADCs clinical pipeline, HER2 has been observed to be the most prominent antigen being targeted by 17% of the ADC candidates. CD22 is another notable target antigen, which is being targeted by 7% of the candidates.
A detailed evaluation of the clinical pipeline highlights that the folate receptor alpha (FolRα)-targeting antibody-drug conjugates (ADC) are currently only being developed for ovarian cancer.
An insightful competitiveness analysis of biological targets, featuring a (A) three-dimensional bubble representation that highlights the targets that are being evaluated for antibody drug conjugates development, taking into consideration number of antibody drug conjugates being developed against them, number of unique target disease indications and number of companies developing antibody-drug conjugates for the target, and (B) a six-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including number of publications, number of grants received to support research on a particular target, number of companies involved in drug development based on a singular target, highest phase of development for the singular target, number of therapies and number of indications.
Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of antibody drug conjugates.
Overall, the ADC therapeutics market is projected to be close to $15 billion by 2030. To get more insights into the ADCs development pipeline, check out the Biopharma detailed report here.
The post ADCs Pipeline Update: Sutro Biopharma Presents Encouraging Data in Patients with Advanced Ovarian Cancer appeared first on Blog.
